海辰药业
(300584)
| 流通市值：23.14亿 | | | 总市值：33.80亿 |
| 流通股本：8213.15万 | | | 总股本：1.20亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 364,148,083.65 | 160,335,652.32 | 671,048,953.77 | 471,526,892.93 |
| 营业收入 | 364,148,083.65 | 160,335,652.32 | 671,048,953.77 | 471,526,892.93 |
| 二、营业总成本 | 311,627,648.84 | 142,276,527.05 | 589,280,857.55 | 424,895,894.17 |
| 营业成本 | 98,395,098.68 | 34,560,181.92 | 117,354,830.34 | 78,373,687.38 |
| 税金及附加 | 6,796,871.57 | 3,596,382.64 | 15,442,631.59 | 10,224,134.89 |
| 销售费用 | 83,211,908.74 | 48,077,744 | 237,191,494.07 | 195,516,916.62 |
| 管理费用 | 110,617,987.53 | 50,082,140.95 | 172,213,376.93 | 104,692,101.85 |
| 研发费用 | 9,888,907.74 | 4,505,218.37 | 40,458,484.11 | 31,204,448.18 |
| 财务费用 | 2,716,874.58 | 1,454,859.17 | 6,620,040.51 | 4,884,605.25 |
| 其中:利息费用 | 2,701,289.79 | 1,445,754.94 | 6,658,907.72 | 4,924,553.61 |
| 其中:利息收入 | 16,519.89 | 10,287.13 | 59,119.82 | 49,557.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -22,693,335.71 | - |
| 加:投资收益 | -1,629,074.36 | -1,469,012.98 | -3,592,696.24 | -2,763,924.66 |
| 资产处置收益 | -1,067.99 | -1,067.99 | 482,279.37 | 482,279.37 |
| 资产减值损失(新) | -6,657,733.57 | -2,035,581.32 | -10,545,747.51 | -14,640,368.67 |
| 信用减值损失(新) | -1,771,122.11 | 478,544.7 | -375,516.89 | 1,442,428.33 |
| 其他收益 | 408,223.16 | 173,906.28 | 1,345,356.28 | 723,521.08 |
| 四、营业利润 | 42,869,659.94 | 15,205,913.96 | 46,388,435.52 | 31,874,934.21 |
| 加:营业外收入 | 66,210.74 | 97,676.27 | 3,793,395.61 | 3,578,515.86 |
| 减:营业外支出 | 4,935,956.95 | 319,131.07 | 2,881,755.94 | 603,476.23 |
| 五、利润总额 | 37,999,913.73 | 14,984,459.16 | 47,300,075.19 | 34,849,973.84 |
| 减:所得税费用 | 5,106,943.62 | -1,349,662.68 | 6,568,034.67 | 2,655,340.7 |
| 六、净利润 | 32,892,970.11 | 16,334,121.84 | 40,732,040.52 | 32,194,633.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 32,892,970.11 | 16,334,121.84 | 40,732,040.52 | 32,194,633.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 32,064,983.55 | 17,362,971.7 | 42,058,385.11 | 32,678,503.32 |
| 少数股东损益 | 827,986.56 | -1,028,849.86 | -1,326,344.59 | -483,870.18 |
| 扣除非经常损益后的净利润 | 36,257,359.28 | 17,515,079.32 | 60,276,671.35 | 29,543,089.6 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.27 | 0.14 | 0.35 | 0.27 |
| (二)稀释每股收益 | 0.27 | 0.14 | 0.35 | 0.27 |
| 九、综合收益总额 | 32,892,970.11 | 16,334,121.84 | 40,732,040.52 | 32,194,633.14 |
| 归属于母公司股东的综合收益总额 | 32,064,983.55 | 17,362,971.7 | 42,058,385.11 | 32,678,503.32 |
| 归属于少数股东的综合收益总额 | 827,986.56 | -1,028,849.86 | -1,326,344.59 | -483,870.18 |
| 公告日期 | 2026-08-25 | 2026-04-25 | 2026-04-25 | 2025-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |